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e-mail address: pjgrassi@libero.it (P. Grassi).Piergiacomo Grassi a,⇑; Alberto Salicone b; Lorenzo Motta b; Mario Salvatore Motta bAbstractTo report a case of central retinal vein occlusion (CRVO) associated with abnormal elevation of Lipoprotein (a) [Lp(a)] plasma levels,
without local or systemic risk factors.
A 74-year-old man was referred to our department for cataract surgery in his left eye, and his anamnesis was negative for systemic
diseases. Two months later, the patient presented with sudden visual loss in his operated eye, and comprehensive ophthalmic
examination was performed, including Fluorescein Angiography (FA) and Optical Coherent Tomography (OCT). Serum concentra-
tions of anticardiolipin and antiphospholipids antibodies, homocysteine and Lp(a) were measured.
Ophthalmoscopy showed the classic features of acute CRVO, FA and OCT confirmed the initial diagnosis. Blood tests were neg-
ative for hyperhomocysteinemia, anticardiolipin and antiphospholipids antibodies, and an abnormal Lp(a) plasma concentration of
1.7 g/L was found. The patient was sent to the internist for further investigation and treatment.
Lp(a) can be an useful marker for early identification of predisposed individuals to CRVO and may be involved in its pathogenesis,
presumably through its pro-atherogenic and antifibrinolytic action.
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Retinal vein occlusion (RVO) is the second most common
retinal vascular disorder after diabetic retinopathy. There
are two types of RVO, central retinal vein occlusion (CRVO)
and branch retinal vein occlusion (BRVO). In CRVO, the major
outflow channel of the eye is obstructed, resulting in effects
throughout the whole retina. In BRVO, a tributary of the cen-
tral retinal vein is obstructed and only the portion of the retinathat is drained by the tributary is affected.1 Besides standard
therapeutic options such as laser photocoagulation and
intravitreal injections, the management of RVO includes the
identification and correction of systemic vascular risk factors
even if no data are available on the possible role of antithrom-
botic strategies in the long-term prevention of recurrent
RVO.2 Risk factors for RVO lead to diffuse vascular endothe-
lium damage that predisposes to thrombosis and include
hypertension, diabetes mellitus, disorders of lipid metabo-e:
al.com
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glaucoma, and conditions that promote a hypercoagulable
state such as deficiency of protein C, protein S, antithrombin
III, and activated protein C resistance. Hyperhomocysteinemia
and vitamins involved in methionine metabolism, altered fibri-
nolysis pathway [elevated levels of PAI-1 and Lp(a)], together
with hemorheologic modifications have been recently consis-
tently associated with the disease.2 Few studies, with conflict-
ing results and conducted in limited study populations, have
hypothesized the role of high levels of Lp(a) in the occurrence
of RVO.3,4 We report a case of ischemic CRVO, presenting in a
patient with anamnesis negative to all classic risk factors,
except for a significant increase in Lp(a) levels. The aim of this
study was to underline the potential role of Lp(a) as an inde-
pendent and highly predictive risk factor for CRVO.Case report
A 74-year-old man was referred to our department for cat-
aract surgery in his left eye. The patient was in good health,
taking no medications. His right eye was aphakic because of a
traumatic cataract removal about twenty years before. Best
corrected visual acuity (BCVA) was 20/30 in his right eye
and 20/100 in his left eye. Slit lamp examination detected
no other ocular abnormalities except for a dense nuclear cat-
aract in his left eye. Intraocular pressure (IOP) and dilated
fundoscopy were normal in both eyes. He underwent routine
uneventful coaxial micro incisional cataract surgery (MICS) in
his left eye. After 2 months, the patient complained of sud-
den visual loss in his left eye, and comprehensive ophthalmic
examination was performed. Fundoscopy showed the classic
features of acute ischemic CRVO: dilated and tortuous veins,
capillary occlusion, papillary and macular edema, hemor-
rhages, exudates and cotton wool patches. Fluorescein
Angiography (FA) and Optical Coherent Tomography (OCT)
confirmed the initial diagnosis. Blood tests were negative
for hyperhomocysteinemia, anticardiolipin and antiphospho-
lipids antibodies, and an abnormal Lp(a) plasma concentra-
tion of 1.7 g/L was found. The patient was sent to the
internist for further investigation and eventual treatment.Discussion
Lp(a) was first isolated by Berg in 1963.5 Lp(a) is a
hepatocytes-synthesized lipoprotein structurally related to
low-density lipoproteins (LDL) and contains, in addition to
cholesterol and apolipoprotein B-100, a surface glycoprotein,
apolipoprotein (a) (Apo A), responsible for its characteristic
properties; in fact, the primary structure of Apo A is similar
to that of plasminogen, a key player in the physiological fib-
rinolysis. DNA of Apo A and DNA of plasminogen are struc-
turally similar and are both located on chromosome 6. The
plasma levels of Lp(a) are genetically determined and extre-
mely variable from one subject to another (from 0.001 to
3 g/L), but very stable over life in the same individual. This
rate is independent of age, sex, smoking, diet, cholesterol
and triglycerides circulating and depends very few on envi-
ronmental factors. Lp(a) is considered an independent risk
factor for thromboembolic diseases.3 The pathophysiological
mechanisms discussed are based on a dual role of Lp(a): an
atherogenic role and an antifibrinolytic role; in fact Lp(a)and its cholesterol are taken up by macrophages that
become foam cells and colonize the vascular endothelium,
thus initiating the process of atherosclerosis. On the other
hand, due to the structural analogy between Apo A and plas-
minogen, Lp(a) presents a striking homology with plasmino-
gen and may therefore compete with binding of
plasminogen at fibrin, leading to fibrinolytic system dysfunc-
tion. In addition, by inhibiting competitively the binding of
plasminogen to its receptors on the surface of endothelial
cells, Lp(a) prevents also the activation of plasminogen by t-
PA. Due to this interaction with fibrinolytic pathway, Lp(a)
has a role in thrombosis in vivo.3
Many studies show that elevated levels of Lp(a) constitute
a risk factor for coronary and brain thromboembolic dis-
eases.3 The great interindividual variability in plasma levels
of Lp(a) precludes defining normal values, but the rate of
Lp(a) is generally considered pathological when it exceeds
0.3 g/L, which is the threshold value beyond which the risk
of heart attack increases. Regarding the risk for RVO, the
threshold value could be 0.1 g/L according to the literature.3
In our case, blood levels of Lp(a) were 1.7 g/L and they rep-
resented the only significantly increased marker of a throm-
botic disease. Surprisingly, RVO occurred in a no-smoker,
no-hyperlipidemic and normotensive patient. Hypertension,
smoking, atherosclerosis and diabetes mellitus are non-
specific markers for RVO, whereas dyslipidemia and hyperho-
mocysteinemia are independent risk factors for the occur-
rence of recurrent CRVO, as shown by Sodi et al.6; in fact,
hypercholesterolemia, hypertriglyceridemia, fasting and
postmethionine hyperhomocysteinemia are more prevalent
in recurrent CRVO patients.6 Marcucci et al. put in evidence
that also vitamins involved in methionine metabolism and
alterations in the fibrinolysis pathway (elevated levels of
PAI-1, deficiency of protein C, of protein S, of antithrombin
III, activated protein C resistance) appear to play a significant
role in the pathogenesis of this disease.2 Elevated levels of
soluble endothelial protein C receptor also seem to be an
important candidate risk factor for CRVO, as shown by
Gumus et al.7 Lp(a) has been shown to be correlated with car-
diovascular disorders and is considered as an emerging
thrombophilic risk factor in the pathogenesis of RVO. In fact,
circulating concentrations of Lp(a) were found to be signifi-
cantly different in a large population of RVO patients when
compared to healthy subjects, independently from other tra-
ditional and emerging risk factors, suggesting that Lp(a) may
play an important and independent role in its pathogenesis.8
Our study found elevated levels of Lp(a) in one patient with
ischemic CRVO, confirming the hypothesis that Lp(a) may
have an independent role in the pathogenesis of this disease,
presumably through its pro-atherogenic and antifibrinolytic
action. Plasma levels of Lp(a) mainly depend on genetic fac-
tors and very few on environmental factors. This probably
explains why the therapeutic methods used against hyper-
lipoproteinemias usually have no influence on plasma levels
of Lp(a) (diet, bile salts chelating resins, HMG CoA reductase,
fish oils, fibrates). Nicotinic acid would cause a decrease of
almost 34% of the concentration of Lp(a), but only the LDL-
apheresis resulted in a decrease of large amplitude. The cur-
rent lack of effective treatments known to reduce levels of Lp
(a) or to fight against the consequences of its pathological
elevation makes the determination of systemic Lp(a) currently
of limited value in clinical practice.
252 P. Grassi et al.In conclusion, identification of independent and highly
predictive risk factors for RVO is nowadays still a big chal-
lenge. The main goals are the preservation of visual acuity
and of visual field, and the prevention of relapses. This study
emphasizes the importance of a systematic control of Lp(a)
blood values, which could be useful for an early identification
of predisposed individuals to CRVO and BRVO, despite their
young age or the absence of other well-known risk factors.
Systematic prospective studies are needed to confirm these
hypotheses and to clarify the proper role of Lp(a) in relation
to other risk factors for RVO.
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